OBIO · Orchestra Biomed Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $110.0K | - | $861.0K | $836.0K | $868.0K | - | $987.0K | $778.0K | $620.0K | - |
| Cost of Revenue | $32.0K | - | $49.0K | $46.0K | $44.0K | - | $68.0K | $44.0K | $34.0K | - |
| Gross Profit | $78.0K | - | $812.0K | $790.0K | $824.0K | - | $919.0K | $734.0K | $586.0K | - |
| R&D | $15.78M | - | $14.03M | $13.85M | $13.48M | - | $11.60M | $11.13M | $9.11M | - |
| SG&A | $6.37M | - | $7.10M | $6.26M | $6.26M | - | $5.67M | $6.47M | $5.90M | - |
| Total Operating Expenses | $22.19M | - | $21.17M | $20.16M | $19.79M | - | $17.33M | $17.64M | $15.04M | - |
| D&A | $90.0K | - | $81.0K | $81.0K | $83.0K | - | $76.0K | $74.0K | $74.0K | - |
| Operating Income | ($22.08M) | - | ($20.31M) | ($19.33M) | ($18.92M) | - | ($16.34M) | ($16.86M) | ($14.42M) | - |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($20.69M) | - | ($20.83M) | ($19.36M) | ($18.75M) | - | ($15.43M) | ($15.98M) | ($13.46M) | - |
| EPS - Basic | ($0.33) | - | ($0.40) | ($0.50) | ($0.49) | - | ($0.41) | ($0.45) | ($0.38) | - |
| EPS - Diluted | ($0.33) | - | ($0.40) | ($0.50) | ($0.49) | - | ($0.41) | ($0.45) | ($0.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.37M | $34.69M | $42.01M | $18.75M | $18.35M | $22.26M | $25.61M | $23.71M | $23.32M | $30.56M |
| Accounts Receivable | $84.0K | $95.0K | $52.0K | $83.0K | $89.0K | $92.0K | $115.0K | $80.0K | $67.0K | $99.0K |
| Inventory | $277.0K | $310.0K | $365.0K | $185.0K | $135.0K | $173.0K | $234.0K | $70.0K | $115.0K | $146.0K |
| Accounts Payable | $6.31M | $6.09M | $8.47M | $5.31M | $5.56M | $5.13M | $4.72M | $6.27M | $3.35M | $2.90M |
| Current Assets | $96.21M | $107.91M | $97.77M | $35.88M | $51.90M | $69.17M | $68.55M | $66.48M | $76.43M | $89.11M |
| Total Assets | $100.66M | $114.86M | $104.81M | $42.83M | $59.05M | $76.17M | $75.32M | $72.38M | $82.63M | $95.21M |
| Current Liabilities | $13.69M | $16.74M | $20.66M | $17.06M | $15.49M | $16.21M | $16.22M | $14.50M | $10.42M | $11.21M |
| Long-term Debt | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M | - | - | - | - |
| Total Liabilities | $49.69M | $51.48M | $61.07M | $42.53M | $42.19M | $43.22M | $29.10M | $28.26M | $25.44M | $27.17M |
| Stockholders' Equity | $41.19M | $53.57M | $43.74M | $295.0K | $16.86M | $32.96M | $46.22M | $44.13M | $57.19M | $68.04M |
| Retained Earnings | ($383.27M) | ($362.58M) | ($368.82M) | ($348.00M) | ($328.63M) | ($309.88M) | ($293.72M) | ($278.30M) | ($262.32M) | ($248.85M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.17M) | - | - | - | ($16.62M) | - | - | - | ($13.11M) | - |
| Investing Cash Flow | $10.32M | - | - | - | $13.00M | - | - | - | $5.86M | - |
| Financing Cash Flow | $5.53M | - | - | - | ($296.0K) | - | - | - | $18.0K | - |
| CapEx | $184.0K | - | - | - | $112.0K | - | - | - | $8.0K | - |
| Free Cash Flow | ($22.35M) | - | - | - | ($16.73M) | - | - | - | ($13.12M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 70.9% | - | 94.3% | 94.5% | 94.9% | - | 93.1% | 94.3% | 94.5% | - |
| Operating margin | -20069.1% | - | -2359.2% | -2311.8% | -2179.8% | - | -1655.7% | -2167.0% | -2326.3% | - |
| EBITDA margin | -19987.3% | - | -2349.8% | -2302.2% | -2170.3% | - | -1648.0% | -2157.5% | -2314.4% | - |
| Net margin | -18810.0% | - | -2419.0% | -2316.1% | -2160.7% | - | -1562.9% | -2054.0% | -2171.5% | - |
| Free cash flow margin | -20320.0% | - | - | - | -1927.2% | - | - | - | -2116.5% | - |
| FCF / Net income | 1.08 | - | - | - | 0.89 | - | - | - | 0.97 | - |
| R&D / Revenue | 14346.4% | - | 1629.2% | 1657.1% | 1553.2% | - | 1174.8% | 1430.1% | 1469.7% | - |
| SG&A / Revenue | 5793.6% | - | 824.4% | 749.3% | 721.5% | - | 574.1% | 831.2% | 951.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -20.6% | - | -19.9% | -45.2% | -31.8% | - | -20.5% | -22.1% | -16.3% | - |
| Return on equity | -50.2% | - | -47.6% | -6563.7% | -111.3% | - | -33.4% | -36.2% | -23.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.03 | 6.45 | 4.73 | 2.10 | 3.35 | 4.27 | 4.23 | 4.58 | 7.34 | 7.95 |
| Quick ratio | 7.01 | 6.43 | 4.72 | 2.09 | 3.34 | 4.26 | 4.21 | 4.58 | 7.33 | 7.94 |
| Cash ratio | 2.07 | 2.07 | 2.03 | 1.10 | 1.18 | 1.37 | 1.58 | 1.63 | 2.24 | 2.73 |
| Leverage | ||||||||||
| Debt / Equity | 0.36 | 0.28 | 0.34 | 50.85 | 0.89 | 0.46 | - | - | - | - |
| Debt / Assets | 0.15 | 0.13 | 0.14 | 0.35 | 0.25 | 0.20 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.44 | 2.14 | 2.40 | 145.17 | 3.50 | 2.31 | 1.63 | 1.64 | 1.44 | 1.40 |
| Liabilities / Assets | 0.49 | 0.45 | 0.58 | 0.99 | 0.71 | 0.57 | 0.39 | 0.39 | 0.31 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.02 | 0.01 | - | 0.01 | 0.01 | 0.01 | - |
| Inventory turnover | 0.12 | - | 0.13 | 0.25 | 0.33 | - | 0.29 | 0.63 | 0.30 | - |
| Days sales outstanding | 279d | - | 22d | 36d | 37d | - | 43d | 38d | 39d | - |
| Days inventory outstanding | 3160d | - | 2719d | 1468d | 1120d | - | 1256d | 581d | 1235d | - |
| Days payable outstanding | 72008d | - | 63115d | 42118d | 46148d | - | 25351d | 52037d | 36006d | - |
| Cash conversion cycle | -68569d | - | -60374d | -40614d | -44990d | - | -24053d | -51419d | -34732d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.5x | - | 3.0x | 348.8x | 9.7x | - | 4.2x | 6.6x | 3.3x | - |
| P / S | 2423.3x | - | 150.3x | 123.1x | 188.5x | - | 195.9x | 375.0x | 304.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -87.3% | - | -12.8% | 7.5% | 40.0% | - | -15.1% | -15.0% | -28.4% | - |
| Revenue CAGR (3y) | -49.7% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -90.5% | - | -11.6% | 7.6% | 40.6% | - | -18.1% | -14.8% | -28.9% | - |
| Operating income growth (YoY) | -16.7% | - | -24.3% | -14.6% | -31.2% | - | -12.5% | -30.1% | -24.9% | - |
| Net income growth (YoY) | -10.3% | - | -35.0% | -21.2% | -39.3% | - | -15.8% | -32.7% | -23.1% | - |
| EPS growth (YoY) | 32.7% | - | 2.4% | -11.1% | -28.9% | - | -7.9% | -28.6% | 5.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -33.6% | - | - | - | -27.5% | - | - | - | 9.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 144.4% | 62.5% | -5.4% | -99.3% | -70.5% | -51.6% | -42.0% | - | -42.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$33.48M totalPartnership Revenue$32.87M · 98.2%
Product$611.0K · 1.8%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Orchestra BioMed Holdings against the 5 most active filers in the same SIC group.